Please use this identifier to cite or link to this item: https://doi.org/10.1016/S0968-0896(01)00267-X
Title: Quinuclidinone O-alkynyloximes with muscarinic agonist activity
Authors: Somanadhan, B.
Loke, W.-K.
Sim, M.-K.
Go, M.-L. 
Issue Date: 2002
Source: Somanadhan, B., Loke, W.-K., Sim, M.-K., Go, M.-L. (2002). Quinuclidinone O-alkynyloximes with muscarinic agonist activity. Bioorganic and Medicinal Chemistry 10 (1) : 207-213. ScholarBank@NUS Repository. https://doi.org/10.1016/S0968-0896(01)00267-X
Abstract: A series of quinuclidinone O-alkynyloximes (14-19) were synthesized and evaluated in radioligand displacement assays for binding affinities to M1-M3 muscarinic receptors. Radioligand displacement assays were carried out using [3H] oxotremorine-M and [3H] pirenzepine on rat cortical tissue and [3H] N-methylscopolamine on rat heart and submandibulary glands. Two alkynyloximes 15 and 18 had pirenzepine/oxotremorine M ratios which were indicative of muscarinic agonist and partial agonist activity, respectively. They were tested for their mnemonic effects in mice using swimming escape task and found to attenuate scopolamine induced impairment of the task in mice at 2 mg/kg. The results show that the O-alkynyloxime moiety linked to aza-cycles of appropriate size and rigidity (for example quinuclidine and tropane) is a potentially useful muscarinic pharmacophore that can be exploited for the design of muscarinic agonists. Copyright © 2001 Elsevier Science Ltd.
Source Title: Bioorganic and Medicinal Chemistry
URI: http://scholarbank.nus.edu.sg/handle/10635/106287
ISSN: 09680896
DOI: 10.1016/S0968-0896(01)00267-X
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

6
checked on Jan 16, 2018

WEB OF SCIENCETM
Citations

4
checked on Dec 13, 2017

Page view(s)

32
checked on Jan 13, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.